Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 10/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591293 | 0.79 | MAP2K1 (0.48) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL29843015 | 0.75 | MAP2K1 (0.74) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL960364 | 0.75 | MAP2K1 (0.74) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL959595 | 0.72 | MAP2K1 (0.55) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL959224 | 0.69 | MAP2K1 (0.54) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL958935 | 0.69 | MAP2K1 (0.62) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL26237957 | 0.68 | MAP2K1 (0.60) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL958976 | 0.68 | MAP2K1 (0.57) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL3123405 | 0.68 | MAP2K1 (0.67) | MAP2K1BRAFRAF1CYP3A4CYP2C9 | |
| SCHEMBL23743850 | 0.68 | KDM4E (0.70) | MAP2K1BRAFRAF1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | IIKURA HITOSHI | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | MAP2K1 3163/4885BRAF 509/4885RAF1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.